Skip to main content
INOVIQ LTD logo

INOVIQ LTD — Investor Relations & Filings

Ticker · IIQ ISIN · AU0000196149 ASX Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2019-10-28 Regulatory Filings
Country AU Australia
Listing ASX IIQ

About INOVIQ LTD

https://www.inoviq.com

INOVIQ LTD specializes in the development and commercialization of next-generation exosome and precision diagnostics. The company focuses on innovative solutions for the early detection and monitoring of cancer and other diseases. Its proprietary technology portfolio includes EXO-NET, a high-throughput exosome capture tool designed for research and clinical applications, and the SubB2M platform, which utilizes an engineered protein to detect the pan-cancer biomarker Neu5Gc. The company also provides the hTERT test for bladder cancer monitoring. These technologies facilitate non-invasive liquid biopsy tests aimed at improving patient outcomes through high sensitivity and specificity. The core business activities encompass the creation of diagnostic tools and research reagents for the global healthcare and life sciences sectors, emphasizing precision medicine and early intervention.

Recent filings

Filing Released Lang Actions
Change in substantial holding 3 pages 202.7KB
Regulatory Filings
2019-10-28 English
Appendix 3Y - Irminger-Finger 2 pages 209.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a change in a director's relevant interests in securities, including the number of shares held before and after the change, the nature of the change, and dates. There is no financial performance data, earnings information, or management discussion. The document is a formal notification of a director's personal share transactions, which fits the definition of Director's Dealing filings. The document length is 3510 characters, which is consistent with a notice rather than a full report. Therefore, the correct classification is Director's Dealing (DIRS).
2019-10-24 English
Notice of Annual General Meeting/Proxy Form 33 pages 514.7KB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' for BARD1 Life Sciences Limited, specifying the date, location, and agenda of the AGM. It includes detailed instructions on voting procedures, proxy appointments, and the agenda items such as adoption of the Remuneration Report, re-election and election of directors, ratification of share placements, approval of placement capacity, approval of an incentive option plan, and approval of increased remuneration for non-executive directors. The document explicitly states it is a notice for the AGM and includes proxy forms and explanatory statements. It does not contain the actual Annual Report or financial statements but refers shareholders to the company's website to access the Annual Report. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting, including notices and proxy forms. The document is not the Annual Report itself (10-K), nor is it a report publication announcement (RPA) because it is a full notice with detailed agenda and voting instructions, not a brief announcement. Therefore, the correct classification is AGM Information (AGM-R).
2019-10-10 English
Phase 3 Assay Development Milestone Reached 2 pages 115.6KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement about reaching a milestone in assay development and extending a contract agreement with Thermo Fisher Scientific. It discusses progress on a research use only (RUO) BARD1 kit and plans for further optimisation and commercialisation. There are no financial statements, regulatory certifications, or detailed financial data. The document is an operational update on a development milestone and contract extension, typical of a Capital/Financing Update or operational progress announcement. It is not an Annual Report, Earnings Release, or any detailed financial report. It is also not a report publication announcement or regulatory filing. Given the focus on contract development and milestone achievement, the best fitting category is Capital/Financing Update (CAP). The document length is about 4868 characters, which is consistent with a detailed announcement but not a full report.
2019-10-07 English
Appendix 3B 13 pages 351.8KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements. It details the issuance of CEO options, the number and class of securities issued, issue prices, and compliance with ASX rules such as rule 7.1 and 7.1A regarding placement capacity. The document is regulatory in nature, providing detailed information about securities issuance and compliance but does not contain financial statements or management discussion. It is not an annual report, earnings release, or management report. It is not a proxy statement or voting results announcement. It is a formal regulatory filing announcing a capital raising event and securities issuance to the ASX. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is not a brief announcement or a report publication announcement but a substantive filing about capital issuance.
2019-10-03 English
Long Term Incentives for CEO 1 page 106.2KB
Remuneration Information Classification · 95% confidence The document is an announcement regarding the grant of long term incentive options to the CEO of BARD1 Life Sciences Limited. It details the terms of the options, including number, exercise price, vesting conditions, and other related information. There is no financial data, no report or results, and no regulatory filing or certification. The content focuses on management compensation and incentive arrangements. This fits best under Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors.
2019-10-02 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.